博暉創新(300318.SZ)斥3000萬元設立全資子公司
格隆匯 10 月 15日丨博暉創新(300318.SZ)公佈,公司出資3000萬元設立全資子公司內蒙古博暉創新生物有限公司。截止公告日,該公司已經完成工商註冊登記手續,並取得了由內蒙古和林格爾新區管理委員會頒發的《營業執照》。
公司名稱:內蒙古博暉創新生物有限公司;經營範圍:醫療器械、醫療分析儀器的技術開發與製造;生物製品的製造、研發及技術服務、技術諮詢;血液製品(技術及進出口服務)(依法須經批准的項目,經相關部門批准後方可開展經營活動)
2020年9月7日,公司與呼和浩特市人民政府、內蒙古和林格爾新區管理委員會共同簽署了《內蒙古和林格爾新區博暉創新生物技術產業基地項目合作框架協議》。根據該戰略框架協議的約定,公司設立了上述子公司並計劃將該公司作為項目公司承擔投資建立現代生物技術產業基地等工作。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.